Compound Screening Development Drugs Protein 
Drug Discovery World
JULY 20, 2023
Chemspace’s compound libraries are now accessible through Arrayjet’s SMM CRO/CMO services for assay development, contract screening and contract array manufacturing. SMMs enable high-throughput screening of compound libraries against targets of interest. PROTAC), and training AI drug discovery models.
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Overcoming sector challenges . Furthermore, the global need is about seven times greater than the US.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 23, 2023
In 2020, AI models predicted the efficacy of repurposed drugs for Covid-19. We witnessed the unprecedented pace of vaccine development, fuelled by cutting-edge mRNA technology. There was an urgent need for quick and adaptable drug discovery in the context of a complex and poorly understood disease.
Drug Discovery World
AUGUST 15, 2023
Can potentially lethal arrhythmias induced by novel drugs be better predicted by using more relevant and sophisticated electrophysiological screening methods? Such techniques, if routinely deployed in drug discovery, may enable improved decision making in predicting serious adverse cardiovascular events.
Drug Discovery World
FEBRUARY 22, 2024
This article is sponsored by Collaborative Drug Discovery. Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. Users can also export data into Excel, so outgoing files can be password protected.
Expert insights. Personalized for you.
40 
Let's personalize your content